Ebola Outbreak Response Underway in Democratic Republic of the Congo
Table of Contents
An outbreak of Ebola virus disease has been declared in the Bulape health zone, Kasai Province, Democratic Republic of the Congo (DRC), prompting a vaccination campaign and deployment of medical resources. The outbreak, caused by the Zaire ebolavirus species, is currently assessed as a high public health risk nationally, moderate regionally, and low globally.
Outbreak Declaration and Initial Response
The DRC Ministry of Public Health officially declared the outbreak on September 12, 2024, following confirmation of cases in Bulape. https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON471 Initial response efforts have focused on containing the spread of the virus through vaccination and providing clinical care to those infected.
Vaccination Campaign
A ring vaccination strategy is being implemented, prioritizing individuals at the highest risk of infection. This includes contacts of confirmed Ebola patients and frontline healthcare workers. The first shipment of 400 doses of the Ervebo Ebola vaccine, drawn from a national stockpile of 2000 doses prepositioned in Kinshasa, has been delivered to Bulape. https://www.who.int/news/item/14-09-2024-ebola-vaccination-begins-in-drc Additional doses are being dispatched to affected areas.
The Ervebo vaccine has demonstrated safety and efficacy against the Zaire ebolavirus. The International coordinating Group on Vaccine Provision has approved the shipment of an additional 45,000 doses to support the ongoing response. https://www.who.int/news/item/14-09-2024-ebola-vaccination-begins-in-drc The World Health Organization (WHO) assisted the DRC health authorities in requesting these additional doses and developing a complete vaccination plan. Teams administering the vaccine are receiving training in data collection and field support.
treatment and Clinical Care
Along with vaccination, treatment courses of the monoclonal antibody therapy Mab114 have been sent to treatment centers in Bulape to provide clinical care for infected patients. https://www.who.int/news/item/14-09-2024-ebola-vaccination-begins-in-drc
WHO support and Regional Preparedness
The WHO has deployed 48 experts specializing in disease surveillance, clinical care, infection prevention and control, logistics, and community engagement to support the DRC government’s outbreak response. These experts are working alongside partner organizations to strengthen measures aimed at halting the virus’s spread.
Recognizing the potential for cross-border transmission, the WHO is also collaborating with national authorities in neighboring countries to enhance operational readiness. This includes bolstering their capacity for rapid case detection and prompt implementation of control measures.
Understanding Ebola Virus Disease
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe and frequently enough fatal illness in humans. The virus is transmitted to people from wild animals and spreads between humans through direct contact with body fluids of infected people, or with contaminated objects (like needles and syringes). https://www.cdc.gov/vhf/ebola/index.html Symptoms include fever, fatigue, muscle pain, headache, and sore throat, which may progress to vomiting, diarrhea, rash, impaired kidney and liver function, and internal and external bleeding.
Current Assessment and Future Outlook
The WHO currently assesses the overall public health risk as high at the national level, moderate at the regional level, and low at the global level.Continued vigilance, rapid response, and international collaboration are crucial to containing this outbreak and preventing further spread. The ongoing vaccination campaign, coupled with robust surveillance and clinical care, offers the best chance of mitigating the impact of this outbreak in the DRC and protecting public health.